Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do

If you’re a psychiatrist or psychiatric nurse practitioner watching the GLP-1 revolution unfold, you’ve probably asked yourself: ‘Can I prescribe these medications? Should I?’

The short answer: Yes, in most cases — but the details matter.

This isn’t about chasing a trend. It’s about recognizing that many of your patients are already dealing with weight issues (often medication-induced), and the boundary between metabolic and mental health is dissolving. GLP-1 agonists like semaglutide (Wegovy, Ozempic) and tirzepatide aren’t just weight-loss drugs anymore — emerging research suggests they may influence mood, cravings, and overall quality of life.

But prescribing weight-loss medications as a psychiatric provider means navigating a regulatory minefield: state-specific scope-of-practice rules, telehealth restrictions, prescribing protocols, and reimbursement complexities that vary wildly depending on where you practice and what letters follow your name (MD vs PMHNP).

This guide breaks down everything you need to know: the clinical rationale, the legal framework state-by-state, the economics of adding weight management to your practice, and how to do it compliantly — whether you’re practicing in-person or via telehealth.

The Clinical Case: Why Psychiatrists Are Prescribing GLP-1s

The Metabolic-Psychiatric Connection

Traditionally, psychiatrists stuck to psychotropics. But the lines are blurring for good reason.

The reality of your patient panel:

• Many psychiatric medications cause significant weight gain (atypical antipsychotics, mood stabilizers, certain antidepressants)
• Obesity itself worsens depression, anxiety, and self-esteem
• Type 2 diabetes and metabolic syndrome are 2-3x more common in people with serious mental illness

You’re already monitoring metabolic labs (glucose, lipids, A1c) for patients on psychiatric meds. You’re already counseling about weight. The question is whether adding a medication primarily indicated for obesity — rather than just referring out — falls within your scope.

Dr. Elliott Lewis, a psychiatrist dual-board certified in obesity medicine, argues it does:

‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense. It’s not about expanding scope to grab more patients — it’s an extension of comprehensive care for the patients I already see.’

He’s not alone. A growing number of psychiatrists are obtaining certification from the American Board of Obesity Medicine (ABOM), which welcomes physicians of any specialty. The training covers obesity science, nutritional interventions, pharmacotherapy, and behavioral strategies — solidifying the legitimacy of psychiatrists treating weight as part of holistic care.

Safety Profile: The Suicidality Concern

Early reports of possible suicidal ideation on GLP-1s spooked many mental health providers. The evidence now is reassuring:

• A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo
• FDA and EMA reviews found no causal link between GLP-1s and suicidal behavior
• In fact, GLP-1-treated groups showed slightly lower rates of depressive symptoms in clinical trials (likely due to improved metabolic health and quality of life)

Potential mental health benefits under investigation:

• Reduced binge-eating impulses
• Decreased cravings in substance use disorders
• Improved mood independent of weight loss (possibly via reduced inflammation and effects on brain reward circuits)

Bottom line: With appropriate monitoring, psychiatrists can feel confident that adding a GLP-1 won’t destabilize a patient’s mental state — and may improve it.

The Competency Question

The pushback you’ll hear: ‘That’s outside your scope — stick to mental health.’

But scope of practice is defined by competency and training, not just specialty tradition. Psychiatrists already manage general medical issues when necessary — checking thyroid function, treating medication side effects, even prescribing metformin for antipsychotic-induced metabolic syndrome.

The key is ensuring competence:

• Take CME courses in obesity medicine (60+ hours for ABOM certification)
• Understand when to refer (e.g., suspected Cushing’s syndrome, complex endocrine issues)
• Collaborate with primary care when appropriate
• Document that the intervention is part of comprehensive patient care

If you’re treating a patient’s depression and their olanzapine-induced 40-pound weight gain is worsening that depression, prescribing a GLP-1 isn’t scope creep — it’s integrated psychiatry.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: Psychiatrists vs PMHNPs

Psychiatrists (MD/DO): Full Authority, State-Specific Rules

Prescriptive Authority:Licensed physicians have broad prescriptive authority in all 50 states. As a psychiatrist, your DEA registration and state medical license allow you to prescribe:

• FDA-approved weight-loss medications (Wegovy, Saxenda, Contrave, Qsymia)
• Off-label GLP-1s (though some states like Mississippi have banned off-label use — more below)
• Controlled substances for weight loss (phentermine, etc.) where not prohibited by state law

No additional certification is legally required to prescribe obesity drugs. However, individual state medical boards impose clinical practice standards (detailed in the State-by-State section) that you must follow — things like:

• Documenting BMI ≥30 (or ≥27 with comorbidity)
• Conducting appropriate physical exams and ruling out secondary causes of obesity
• Obtaining informed consent
• Scheduling regular follow-ups
• Avoiding prohibited drug combinations or uses

Violating these standards can trigger board investigations, even if you’re legally allowed to prescribe.

PMHNPs: It Depends Where You Practice

For psychiatric nurse practitioners, prescribing weight-loss medications is a state-by-state story with three basic tiers:

Tier 1: Full Practice Authority States (~26 states + DC)

In states like Washington, Oregon, Colorado, Arizona, New Mexico, Montana, Wyoming, Iowa, Minnesota, Wisconsin, Michigan, Maryland, Delaware, Rhode Island, Connecticut, Vermont, New Hampshire, Maine, Alaska, Hawaii, and DC, experienced NPs can practice and prescribe independently after meeting requirements (typically 2,000-4,000 hours of supervised practice).

What this means:

• You can prescribe GLP-1s, phentermine, and other weight-loss meds without a physician collaborator
• No legal requirement for MD oversight or protocols
• You still need appropriate training/competency (same professional standard as MDs)

Practical caveat: Even in FPA states, some insurers and pharmacies may push back on expensive GLP-1 prescriptions from NPs, requesting physician sign-off. This isn’t law, but it happens — especially for prior authorizations on drugs like Wegovy.

Tier 2: Reduced Practice States (Transitioning to Independence)

States like New York, Illinois, California allow NP independence after meeting experience thresholds:

New York: After 3,600 hours of practice, NPs can work independently without a collaborating physician. Before that, you need a written collaborative agreement.

Illinois: NPs with ≥4,000 hours of experience + 250 hours of CE can apply for Full Practice Authority. Until then, you need a collaborative agreement that specifies which controlled substances you can prescribe.

California: AB 890 allows certain NPs to practice independently after 3 years/4,600 hours of supervised practice. ‘103’ NPs (practicing in qualifying settings) started in 2023; ‘104’ NPs (independent practice, including opening clinics) begins January 1, 2026. However: California’s Corporate Practice of Medicine doctrine means even independent NPs can’t own medical practices — you still need physician involvement at the business/clinic level.

Tier 3: Restricted Practice States (Mandatory Collaboration)

States like Texas, Florida, Alabama, Georgia require all NPs to have physician oversight for prescribing:

Texas: Every NP must have a Prescriptive Authority Agreement with a Texas-licensed physician. The agreement must detail:

• Scope of prescribing (including specific drug classes like Schedule IV anorectics)
• Communication/consultation protocols
• Monthly quality review meetings
• Chart review requirements

One physician can supervise up to 7 NP/PA prescribers in Texas (in non-hospital settings).

Florida: APRNs must practice under written protocols with a supervising physician (or qualify for limited Autonomous Practice, which doesn’t apply to psychiatric NPs and excludes controlled substances). Florida caps supervision at 1 physician : 4 APRNs for indirect supervision.

Important: Even with a collaborating physician, you’re still responsible for practicing within your competency. A collaboration agreement that says you can prescribe weight-loss meds doesn’t mean you should without proper training.

The Specialty Scope Question for PMHNPs

Here’s a nuance many miss: Your NP license allows you to prescribe within your education and competency, not just your specialty certification.

A PMHNP prescribing metformin to counter antipsychotic weight gain? Defensible — it’s managing a side effect of psychiatric treatment.

A PMHNP opening a standalone weight-loss clinic for the general public with no mental health component? That could raise eyebrows with your state board of nursing.

The safe approach:

• Frame weight management as part of integrated psychiatric care for your existing patients
• Pursue additional training (obesity medicine CME, ABOM certification)
• If you want to make weight management a major service line, get explicit permission in your collaborative agreement (if required) and ensure your collaborating physician has obesity medicine expertise

Telehealth Prescribing: Federal Green Lights, State Red Lights

The Federal Framework (Through 2025)

During COVID-19, the DEA waived the Ryan Haight Act requirement for an in-person exam before prescribing controlled substances. The good news: This waiver has been extended multiple times and currently runs through December 31, 2025 (and will likely be extended again).

This federal waiver allows providers nationwide to:

• Prescribe Schedule II-V controlled substances via telehealth
• Use audio-video telehealth to establish the patient relationship
• Skip the initial in-person exam requirement

Important: The DEA explicitly states this applies only if state law also allows it. That’s where things get complicated.

State-Level Telehealth Traps

Despite federal permission, about 8-10 states have enacted stricter telemedicine laws that override the DEA waiver. For weight-loss prescribing, the two biggest traps are:

Florida: No Controlled Substances via Telehealth (With Limited Exceptions)

Florida Statute 456.47 prohibits prescribing controlled substances via telehealth except for:

• Treatment of psychiatric disorders
• Inpatient/hospice care
• Emergency addiction treatment

The problem: Weight loss isn’t on that list. So even though the DEA says you can prescribe phentermine (Schedule IV) via telehealth, Florida law says you can’t — unless you can argue it’s part of psychiatric treatment (risky without clear guidance).

The workaround: Many Florida telehealth providers:

• Only prescribe non-controlled GLP-1s (semaglutide, liraglutide) via telehealth — perfectly legal
• Require an in-person visit (can be with a local physician or delegated to an APRN/PA) before prescribing any controlled appetite suppressant
• Partner with Florida-licensed physicians who conduct the initial evaluation

Alabama, South Carolina, Idaho: In-Person Exam Required

These states mandate an initial in-person physical exam before prescribing controlled substances, regardless of federal waivers. For telehealth weight-loss services, this means:

• A local provider must see the patient first
• Telehealth follow-ups are fine, but you can’t do a pure remote start for phentermine

The full list of restrictive states: Florida, Alabama, South Carolina, Idaho, and a few others with nuanced rules (Arkansas, Louisiana in some cases). Always check current state telehealth law before launching services in a new state.

Establishing a Valid Telehealth Relationship

Even in telehealth-friendly states, you must meet the standard of care for prescribing weight-loss medications. Most states accept that a video consultation can establish a valid patient-provider relationship, but:

Best practices:

• Document a comprehensive history: Current weight, weight history, diet/exercise attempts, medical comorbidities (diabetes, hypertension, sleep apnea), psychiatric history, current medications
• Conduct a visual exam: Assess habitus, ask patient to self-report current weight and vital signs (or coordinate with a local pharmacy/lab)
• Review or order labs: TSH (rule out hypothyroidism), fasting glucose/A1c, lipid panel, liver/kidney function
• Obtain informed consent: Document discussion of risks, benefits, alternatives, and expected outcomes
• Create a treatment plan: Include dietary/exercise counseling (can be delegated to a health coach or dietitian, but must be documented)

Asynchronous-only prescribing is risky. In May 2023, a Mississippi doctor lost his license for prescribing Ozempic through an instant-messaging platform with no audio/video. State boards view questionnaire-only prescribing as failing to establish an adequate patient relationship.

State-Specific Prescribing Protocols (Examples)

Beyond telehealth modality rules, many states have clinical practice standards for weight-loss prescribing:

Florida’s Obesity Drug Rule (Fla. Admin. Code 64B15-14.004)

Before prescribing any anti-obesity medication:

• Document BMI ≥30, or ≥25 with obesity-related comorbidity (diabetes, hypertension, dyslipidemia, sleep apnea)
• Conduct or document a comprehensive exam (can be delegated to an APRN/PA under your supervision)
• Rule out secondary causes (hypothyroidism, Cushing’s, etc.)
• Obtain written informed consent and provide Florida’s Weight-Loss Consumer Bill of Rights
• Schedule follow-ups at least every 3 months for patients on continuous therapy
• Check the PDMP (E-FORCSE) before each controlled substance prescription

Enforcement: Florida is serious about this. Clinics have been cited for:

• Prescribing to patients who didn’t meet BMI criteria
• Failing to do follow-ups within 3 months
• Not documenting informed consent

New Jersey’s Comprehensive Approach

New Jersey requires:

• Complete physical exam and appropriate lab tests
• Assessment for underlying psychiatric conditions (and treating or stabilizing them before or alongside weight-loss medication)
• Nutritional counseling, exercise plan, and behavior modification recommendations (not just pills)
• Ongoing monitoring documented at each visit

This is actually a natural fit for psychiatric providers — you’re already equipped to handle the mental health screening and behavioral support.

Virginia’s Monthly Check-In Requirement

Virginia’s Board of Medicine requires:

• Follow-up within 30 days of starting weight-loss medication
• Monthly evaluations for the first several months
• Documentation of diet and exercise program for each patient

For telehealth providers, this means scheduling monthly video visits during the initiation phase (can transition to quarterly once stable).

Mississippi’s Off-Label Ban

In August 2023, Mississippi banned off-label prescribing of GLP-1 agonists solely for weight loss. You must use FDA-approved obesity drugs (Wegovy for weight loss, not Ozempic unless treating diabetes).

The rationale: Concerns about safety and the fact that Wegovy is specifically formulated and studied for obesity at the 2.4mg dose, while Ozempic is approved for diabetes at lower doses.

Practical impact: Mississippi providers must ensure they’re prescribing the right product for the right indication. This may become a trend in other states.

PDMP Requirements

Almost every state requires checking the Prescription Drug Monitoring Program before prescribing controlled substances. For phentermine (Schedule IV):

States with mandatory PDMP checks for all controlled substances:

• Florida (E-FORCSE)
• New York (I-STOP)
• Texas (PMP)
• Illinois (PMP)
• Pennsylvania (some Schedule II/III mandatory, best practice for all)

Most EHR systems can integrate PDMP checks. Document the check in your note — it’s required for compliance and protects you in case of audit.

The Economics: Reimbursement and Revenue Models

Insurance Coverage Is Expanding Rapidly

The old world (pre-2024):Most commercial insurers excluded weight-loss medications as ‘not medically necessary.’ Medicare explicitly banned coverage. Patients paid $1,000-1,500/month out of pocket or went to cash-pay telehealth clinics.

The new world (2025-2026):

• Medicare will begin covering anti-obesity medications (Wegovy, Mounjaro, etc.) following price negotiations announced in late 2025
• Many commercial insurers now cover GLP-1s with prior authorization (typically requiring BMI ≥30 or ≥27 with comorbidity)
• State Medicaid programs are expanding coverage (varies by state, but momentum is building)

What prior authorizations typically require:

• Documentation of BMI and weight history
• Evidence of lifestyle modification attempts (diet, exercise programs)
• Absence of contraindications (pregnancy, medullary thyroid cancer history, etc.)
• Sometimes, participation in a structured weight management program

Psychiatrists and PMHNPs should be prepared to:

• Fill out detailed PA forms
• Document comprehensive treatment plans (not just ‘patient wants to lose weight’)
• Coordinate with dietitians or health coaches if insurers require multidisciplinary care

Billing for Weight Management Visits

E/M Codes:Most weight management consultations are billed using standard evaluation and management codes:

• 99202-99205: New patient visits (initial consult: typically 99203 or 99204, ~$150-200 Medicare reimbursement)
• 99212-99215: Established patient visits (follow-ups: typically 99213 for 15-20 min med checks, ~$75-120 Medicare)

Obesity-Specific Codes:

• G0447: Face-to-face behavioral counseling for obesity, 15 minutes (Medicare pays ~$25-30)
• Can be billed in addition to E/M if you provide separate intensive behavioral counseling beyond medication management

Psychiatric Codes:If you’re combining weight management with psychiatric medication management in the same visit:

• Use psychiatric evaluation codes (90792 for initial, ~$200) or
• Time-based E/M codes that include both medical decision-making for psych meds and metabolic management

Telehealth Modifiers:Add modifier 95 or GT (depending on payer) to indicate the visit was via telehealth. Most states with telehealth parity laws require insurers to reimburse at the same rate as in-person.

Telehealth Parity by State (Priority States)

Medicare telehealth extensions (through 2025, likely 2026): Medicare pays telehealth visits at office (non-facility) rates and allows mental health visits to patient homes with no geographic restrictions.

MD vs NP Reimbursement

Psychiatrists (MD/DO):

• Reimbursed at 100% of physician fee schedule by Medicare and most commercial payers
• Example: A 99214 visit might pay $125-150 depending on location

PMHNPs:

• Medicare reimburses NP services at 85% of physician fee schedule
• Some private insurers pay 85-100% depending on contract
• Illinois Medicaid pays NPs at 100% of physician rates (progressive policy)

Practical impact: For high-volume telehealth practices, this 15% difference can add up, but NPs often have lower overhead (salary, malpractice). Many platforms use blended teams (MDs for complex cases, NPs for routine med management) to optimize economics.

Cash Pay vs Insurance: What Works?

Cash-pay telehealth weight loss was the early model (companies like Ro, Hims, Calibrate):

• Monthly membership fee ($50-200)
• Plus cost of medication (either marked up through compounding pharmacies or retail GLP-1s)
• Patients pay out of pocket entirely

Pros:

• No insurance billing hassle
• Higher margins per patient if you mark up medications

Cons:

• Limited to affluent patients
• High churn when patients can’t afford $300-500/month ongoing
• Regulatory scrutiny (many compounded semaglutide products were investigated for safety)

Insurance-based model is becoming more viable:

• Bill insurance for visits (E/M codes)
• Send GLP-1 prescription to patient’s pharmacy (they use insurance for medication)
• You get paid per visit (~$100-150), patient pays copay

Pros:

• Larger addressable market (anyone with obesity diagnosis and insurance)
• More sustainable (patients can afford to stay on therapy long-term)
• Less regulatory risk (using FDA-approved products through licensed pharmacies)

Cons:

• Prior authorization burden
• Payment delays from insurers
• Need credentialing with multiple payers

Hybrid approach: Some practices bill insurance when possible, offer cash-pay as backup for patients with exclusions.

State-by-State Compliance Guide (Priority States)

California

NP Scope:

• Currently: NPs need physician-approved ‘standardized procedures’ for prescribing
• Jan 1, 2026: ‘104’ NPs (independent practice after 4,600 hours + training) can practice without physician oversight
• Controlled substances: Until fully independent, NPs cannot prescribe controlled substances without physician delegation

Physician Requirements:

• Corporate Practice of Medicine: Only physicians can own medical practices in CA
• Even independent NPs must work within physician-owned entities or professional corporations

Weight-Loss Prescribing:

• No CA-specific obesity drug rules
• Follow standard of care (BMI criteria, comprehensive workup)
• Telehealth allowed; CA has strong telehealth parity

Telehealth:

• No restrictions on prescribing via telehealth (controlled or non-controlled)
• Commercial payers must reimburse telehealth equal to in-person

Bottom line: CA is moving toward NP independence, but CPOM means you’ll always need physician involvement at the business level. For weight management, psychiatrists have full authority; NPs should partner with MDs until 2026+ reforms clarify.

Texas

NP Scope:

• Strict collaboration required: All NPs must have Prescriptive Authority Agreement with a Texas-licensed physician
• Agreement must detail prescribing scope, monthly quality reviews, chart audits
• One physician can supervise up to 7 NP/PA prescribers (non-hospital)

Physician Requirements:

• Corporate Practice of Medicine: Medical decisions must be under physician control
• Non-physician-owned clinics use MSO model + physician medical director

Weight-Loss Prescribing:

• Texas prohibits Schedule II stimulants (amphetamines) for weight loss
• Phentermine (Schedule IV) and GLP-1s allowed with proper indication
• NPs must have explicit authorization in PAA to prescribe weight-loss meds

Telehealth:

• Allowed if standard of care met
• PMP check required for controlled substances
• No state prohibition on controlled substance prescribing via telehealth (federal waiver applies)

Bottom line: Texas requires tight physician oversight. For telehealth weight-loss, you need a Texas-licensed MD collaborating with any NPs. High demand (35% obesity rate) but strict compliance environment.

Florida

NP Scope:

• APRNs must practice under written protocol with supervising physician
• Limited ‘Autonomous Practice’ available for primary care NPs only (excludes PMHNPs)
• Even autonomous NPs cannot prescribe controlled substances independently

Physician Requirements:

• Weight-loss clinics must have Florida-licensed MD medical director (Health Care Clinic Act)
• Clinic license required if offering weight-loss treatments for fee

Weight-Loss Prescribing:

• Strict rules (Fla. Admin. Code 64B15-14.004):
• BMI ≥30 or ≥25 + comorbidity
• Comprehensive exam (can be delegated to APRN/PA)
• Written informed consent + Weight-Loss Consumer Bill of Rights
• Follow-ups every 3 months minimum
• PDMP (E-FORCSE) check before each controlled substance Rx

Telehealth:

• Controlled substances CANNOT be prescribed via telehealth (except psychiatric disorders, inpatient, addiction treatment)
• Weight loss not on exception list → phentermine via telehealth is illegal in FL
• GLP-1s (non-controlled) CAN be prescribed via telehealth with proper exam
• Out-of-state providers must register with FL Dept of Health

Bottom line: Florida is the most restrictive state. You can do GLP-1 telehealth, but not phentermine. Always need MD supervision for NPs. High enforcement risk — follow the rules to the letter.

New York

NP Scope:

• Reduced practice: NPs need collaborative agreement initially
• After 3,600 hours (NP Modernization Act), can practice independently
• No formal caps on collaborating physicians

Physician Requirements:

• No CPOM ban — experienced NPs can own practices
• Weight management clinics don’t require physician ownership

Weight-Loss Prescribing:

• No NY-specific obesity drug rules
• Follow national guidelines (BMI criteria, informed consent)
• I-STOP (PMP) check required before any Schedule II-IV prescription (including phentermine)

Telehealth:

• Very supportive environment
• Payment parity law (2022) for commercial insurance
• No state restrictions on controlled substance prescribing via telehealth (follows federal rules)
• Medicaid covers telehealth broadly

Bottom line: NY is telehealth-friendly with growing NP autonomy. Good market for both MDs and experienced NPs. No special hurdles beyond standard PMP checks.

Pennsylvania

NP Scope:

• Collaborative agreement required for all CRNPs
• No FPA (legislation proposed but not passed)
• Physician must be available for consultation; one MD can collaborate with 4 NPs

Physician Requirements:

• Prescription blanks must include both CRNP name and collaborating physician name
• Physician must review sample of charts regularly

Weight-Loss Prescribing:

• No PA-specific obesity drug rules
• Follow standard of care
• Collaborative agreement should specify authority to prescribe weight-loss meds

Telehealth:

• Relatively open to telehealth
• No comprehensive parity statute (yet)
• Act 69 (2020): Tele-mental health payment parity
• No state restrictions on controlled substance prescribing via telehealth
• Medicaid reimburses telehealth

Bottom line: PA requires physician collaboration for all NPs. Good telehealth environment but need to secure collaborating physician relationships. FPA advocacy ongoing — landscape may shift.

Illinois

NP Scope:

• Partial FPA: APRNs with ≥4,000 hours + 250 CE hours can apply for Full Practice Authority
• FPA APRNs can prescribe independently (including controlled substances)
• Less experienced APRNs need collaborative agreement

Physician Requirements:

• FPA APRNs are independent (no physician ownership requirement)
• Collaborative agreements (when required) must specify controlled substance authority

Weight-Loss Prescribing:

• No IL-specific obesity drug rules
• Separate Controlled Substance license required for prescribing CS
• FPA APRNs need 45 hours pharmacology training for Schedule II + consultation relationship for first year

Telehealth:

• Strong support: Telehealth Alignment Act (2021)
• Payment parity mandated for commercial plans
• Illinois Medicaid pays APRNs at 100% of physician rates (excellent for NPs)
• No state restrictions on controlled substance prescribing via telehealth

Bottom line: IL is one of the best states for experienced NPs — true independence possible, excellent Medicaid reimbursement. Great telehealth infrastructure. Good market opportunity for both MDs and APRNs.

FAQ: Weight Loss Prescribing for Psychiatric Providers

Can a psychiatrist prescribe Wegovy or Ozempic for weight loss?

Yes. Psychiatrists have full prescriptive authority for FDA-approved obesity medications and can use clinical judgment for off-label use (though some states like Mississippi prohibit off-label GLP-1s for weight loss).

The key is ensuring you have appropriate training (through CME, ABOM certification, or mentorship) and can document that you’ve met the standard of care (comprehensive workup, informed consent, monitoring plan).

Can a PMHNP prescribe GLP-1 medications independently?

It depends on your state:

• Full practice states (like WA, OR, AZ, NM, IA, MN, WI, MI, MD, DE, RI, CT, VT, NH, ME, AK, HI, DC): Yes, after meeting experience requirements
• Reduced practice states (NY, IL after 3,600-4,000 hours): Yes, once you’ve achieved independence
• Restricted practice states (TX, FL, AL, GA, etc.): No — you need a collaborating physician and explicit authority in your practice agreement

Even in independent states, ensure you have competency in obesity treatment (consider additional training) and be aware some insurers/pharmacies may request physician involvement for expensive GLP-1 scripts.

Is it within a PMHNP’s scope to treat obesity, or is that outside psychiatric specialty?

Nuanced answer:

Scope of practice is about competency and training, not just specialty title. A PMHNP can defensibly prescribe weight-loss medications when:

• It’s part of integrated care for psychiatric patients (e.g., managing antipsychotic-induced weight gain)
• You have additional training in obesity medicine
• It’s within your state’s legal scope and any collaborative agreement

Opening a standalone weight-loss clinic with no mental health component might raise questions. Best approach: Frame weight management as part of comprehensive psychiatric care and ensure you can demonstrate competency if questioned.

Can I prescribe phentermine via telehealth?

Federally: Yes, through December 31, 2025 (DEA waiver allows controlled substance prescribing via telehealth without initial in-person exam).

State level:

• Allowed in most states (TX, NY, PA, IL, CA, etc.)
• Prohibited in: Florida (weight loss not a covered exception), Alabama, South Carolina, Idaho, and a few others requiring in-person exam

Always check your state’s specific telehealth controlled substance rules before prescribing phentermine remotely.

Do I need special certification to prescribe weight-loss medications?

Legally: No additional certification required beyond your medical license and DEA registration.

Practically: Strong recommendation to pursue:

• CME in obesity medicine (60+ hours for ABOM certification)
• Obesity Medicine Board Certification (ABOM) — open to all physicians including psychiatrists
• Specialized training for NPs through organizations like American Association of Nurse Practitioners

This training:

• Solidifies your competency if questioned
• Helps you navigate complex cases safely
• Improves patient outcomes (obesity treatment is more than just prescribing)

What are the reimbursement rates for weight management visits?

Medicare/Commercial rates (approximate):

• Initial consultation (99203-99204): $150-200
• Follow-up med management (99213-99214): $75-150
• Obesity counseling (G0447): $25-30 per 15-minute session

MD vs NP:

• Psychiatrists: 100% of fee schedule
• PMHNPs: 85% from Medicare, 85-100% from commercial (varies)
• Illinois Medicaid pays NPs 100% (unique)

Volume economics:If you see 4-5 weight management patients per day at $100-125 per visit, that’s $400-625 daily revenue, or ~$8,000-12,000/month (part-time). Combined with psychiatric practice, this can be meaningful supplemental income.

Do insurance companies cover GLP-1 medications for weight loss?

Increasingly, yes:

• Medicare will begin covering anti-obesity medications in 2026 following price negotiations
• Most major commercial insurers now cover Wegovy, Saxenda, and similar with prior authorization
• Typical PA requirements: BMI ≥30 or ≥27 + comorbidity, documentation of lifestyle interventions, absence of

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting